Domestic and Overseas Venture Investment and Growth Support through MEDIPAL Innovation Fund
First written in FY2021. 6 of 7 entries say "Advanced", first in FY2022-Q2. Latest entry: FY2024.
The whole theme swung hardest in 2018: 1 of 6 companies on the "Worse" side.
11 other companies' latest entry also says "Advanced".
- FY2024AdvancedAnnual report
「In addition, the company invests in domestic venture companies through MEDIPAL Innovation Investment Limited Partnership, seeking to expand its earnings base and maximize corporate value while contributing to the creation of a sustainable economic society.」
The company indicated that continued venture investment through MEDIPAL Innovation Investment Limited Partnership would contribute to expanding its earnings base and maximizing corporate value under its 2027 Medium-Term Vision. - FY2023-Q2AdvancedAnnual report
「In May 2022, through MEDIPAL Innovation Investment Limited Partnership, the company invested in Chordia Therapeutics Co., Ltd. (Fujisawa, Kanagawa), a biotech venture specializing in cancer research and development, and entered into a basic agreement with the company concerning a business alliance. In August of the same year, it invested in Noile-Immune Biotech Inc. (Minato-ku, Tokyo), which develops novel cancer immunotherapies centered on CAR-T cell therapy, and in September of the same year, it invested in Evec, Inc. (Chuo-ku, Sapporo), which conducts research and development of fully human antibodies derived from human peripheral blood for pharmaceutical applications. The company will continue to consider investing in a range of venture companies.」
MEDIPAL Innovation Investment Limited Partnership expanded its portfolio beyond Chordia to Noile-Immune Biotech in August 2022 and Evec in September of the same year. Its investment track record now includes research and development in cancer immunotherapy and fully human antibodies. - FY2023-Q1AdvancedAnnual report
「In May 2022, with the aim of expanding its earnings base, the company invested through MEDIPAL Innovation Investment Limited Partnership in Chordia Therapeutics Co., Ltd. (Fujisawa, Kanagawa; hereinafter, Chordia), a biotech venture specializing in cancer research and development. The company also entered into a basic agreement with Chordia concerning a business alliance.」
MEDIPAL Innovation Investment Limited Partnership expanded its investment portfolio from medical devices, healthcare IT and regenerative medicine to Chordia, a company specializing in cancer research and development. In addition to the investment, it entered into a basic agreement for a business alliance. - FY2022AdvancedAnnual report
「The company invested in several promising venture companies in the medical-device, healthcare IT and regenerative-medicine fields through MEDIPAL Innovation Investment Limited Partnership, which it established jointly with SBI Investment Co., Ltd. (Minato-ku, Tokyo).」
Through MEDIPAL Innovation Investment Limited Partnership, the company invested in several ventures in the medical-device, healthcare IT and regenerative-medicine fields. - FY2022-Q3AdvancedAnnual report
「In addition, as investments made through MEDIPAL Innovation Investment Limited Partnership, which we jointly established with ＳＢＩインベストメント株式会社 (Minato-ku, Tokyo, hereinafter ＳＢＩインベストメント), we invested in Holoeyes株式会社 (Minato-ku, Tokyo), a medical IT venture, in November of the same year, and in イノバセル株式会社 (Shibuya-ku, Tokyo), a regenerative medicine venture, in December. Going forward, we will continue to examine potential investments in a range of venture companies, leveraging the diverse sourcing capabilities of ＳＢＩインベストメント.」
Following its first investment in Riverfield, MEDIPAL Innovation Investment Limited Partnership invested in Holoeyes, a healthcare IT venture, and Inovasel, a regenerative-medicine venture. - FY2022-Q2AdvancedAnnual report
「In September of the same year, as the first investment by MEDIPAL Innovation Investment Limited Partnership, established jointly with SBI Investment Co., Ltd. (Minato-ku, Tokyo), the company invested in Riverfield Inc. (Shinjuku-ku, Tokyo), a medical-device venture. It will continue to consider investments in a range of venture companies by leveraging SBI Investment Co., Ltd.'s diverse sourcing capabilities.」
MEDIPAL Innovation Investment Limited Partnership made its first investment in a medical-device venture in September 2021 and indicated a policy of continuing to identify and invest in portfolio companies. - FY2021First statedAnnual report
「In March 2021, the company and SBI Investment Co., Ltd. (Minato-ku, Tokyo), a wholly owned subsidiary of SBI Holdings, Inc. (Minato-ku, Tokyo), jointly established the CVC (corporate venture capital) fund MEDIPAL Innovation Fund. Through the fund, they will invest in and support the growth of venture companies in Japan and overseas.」
The company jointly established a CVC fund with SBI Investment and launched a framework for investing in and supporting the growth of domestic and overseas ventures.